Bad News For Amylyx As EMA Upholds Rejection Of ALS Drug Albrioza

 
• By Eliza Slawther

The European Medicines Agency stood by its initial decision to recommend against EU approval of Amylyx’s ALS drug Albrioza after a re-examination, but the company remains hopeful that further trial evidence could support a future EU authorization.

Dislike sign, thumb down
• Source: Shutterstock/meikesen

More from Europe

More from Geography